Tributylhexadecylphosphonium Bromide, a Novel Nuclear Factor of Activated T Cells Signaling Inhibitor, Blocks Interleukin-2 Induction Associated with Inhibition of p70 Ribosomal Protein S6 Kinase Phosphorylation
Hiroshi Umehara(University of Shizuoka), Akira Asai(University of Shizuoka)
Cited by 4
Related Papers
Inhibition of STAT3 by Anticancer Drug Bendamustine
|PLoS ONE|2017|16
Discovery of a New STAT3 Inhibitor Acting on the Linker Domain
|Biological and Pharmaceutical Bulletin|2019|13
Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines
|Scientific Reports|2021|12
Visualization and quantification of dynamic STAT3 homodimerization in living cells using homoFluoppi
|Scientific Reports|2018|11
Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models
|Cancer Immunology Immunotherapy|2023|4